What is the acute management for a patient presenting with a seizure, loss of consciousness, and intracranial hemorrhage?

Acute Management of Seizure, Loss of Consciousness, and Intracranial Hemorrhage

For a patient presenting with seizure, loss of consciousness, and intracranial hemorrhage, immediately administer antiseizure medication to treat the clinical seizure, avoid prophylactic antiseizure drugs if no seizures occur, aggressively manage blood pressure and intracranial pressure, and consider continuous EEG monitoring for at least 24 hours if mental status remains impaired. 1

Immediate Seizure Management

Active Seizure Treatment

• Administer benzodiazepines immediately for any witnessed or ongoing seizure activity, as this represents status epilepticus requiring urgent termination 2, 3
• Provide supplemental oxygen and assess airway protection; consider intubation if the patient cannot protect their airway 3, 4
• Check fingerstick glucose immediately to rule out hypoglycemia as a reversible cause 3, 4
• Establish IV access if not already present 3

Second-Line Antiseizure Medications

If seizures persist after benzodiazepines (benzodiazepine-refractory status epilepticus):

• Use levetiracetam, fosphenytoin, or valproate as second-line agents—all three medications result in seizure cessation in approximately 50% of patients 2
• These three medications show equivalent efficacy, with no significant difference in outcomes 2
• Levetiracetam may be preferred over phenytoin/fosphenytoin due to fewer adverse effects, though evidence is limited 5

Seizure Prophylaxis Decision-Making

When to AVOID Prophylactic Antiseizure Medications

Do not administer prophylactic antiseizure medications in patients with intracerebral hemorrhage who have not had clinical or electrographic seizures 1, 5

The evidence strongly supports this recommendation:

• Prophylactic antiseizure medications do not improve functional outcomes, long-term seizure control, or mortality 1
• Meta-analyses demonstrate increased adverse events and higher risk of poor functional outcomes at 90 days with prophylactic use 5
• The 2025 Neurocritical Care Society guidelines explicitly recommend against routine prophylaxis 5
• The 2022 AHA/ASA Stroke guidelines give prophylactic antiseizure medication a Class 3 (No Benefit) recommendation 1

When Antiseizure Medications ARE Indicated

Administer antiseizure medications only in these specific circumstances:

• Clinical seizures witnessed or reported (Class 1 recommendation) 1
• Electrographic seizures confirmed on EEG with impaired consciousness (Class 1 recommendation) 1
• If prophylaxis is used despite guidelines (in high-risk patients), limit duration to ≤7 days and use levetiracetam over phenytoin 5

High-Risk Patients Requiring Closer Monitoring

While prophylaxis is not recommended, certain patients warrant heightened surveillance 6, 7, 8:

• Lobar hemorrhage location (cortical involvement significantly increases seizure risk) 7, 8
• Younger age (<65 years) with lobar hemorrhage 8
• Large hematoma volume (≥10 mL) 8
• Intraventricular extension 6

Note: Even in these high-risk patients, one 2025 study suggested prophylaxis reduced early seizures in lobar hemorrhages, but this contradicts guideline recommendations and requires shared decision-making 8

EEG Monitoring Strategy

Indications for Continuous EEG

Obtain continuous EEG monitoring (≥24 hours) in patients with: 1

• Unexplained impaired or fluctuating mental status
• Suspicion of non-convulsive seizures
• Comatose patients (may require prolonged monitoring beyond 24 hours) 1

Rationale

• Subclinical or non-convulsive seizures occur in up to 30% of intracerebral hemorrhage patients when continuous EEG is used 6
• Most seizures in intracerebral hemorrhage occur within the first 24-72 hours 6, 7
• Loss of consciousness in this clinical scenario may represent ongoing seizure activity rather than solely hemorrhage effects 1

Critical Hemorrhage Management Priorities

Blood Pressure Control

• Control severe hypertension to prevent hematoma expansion, which commonly occurs in the first hours and strongly predicts mortality 9, 3
• Hematoma expansion is a major driver of poor outcomes 9, 3

Intracranial Pressure Management

• Monitor and manage elevated intracranial pressure from mass effect 9, 3
• Consider neurosurgical consultation promptly for potential intervention 9, 3

Anticoagulation Reversal

• Reverse anticoagulant effects immediately if applicable 9, 3

Temperature Control

• Treat elevated temperature (≥37.7-38.3°C), as fever is associated with worse outcomes in intracerebral hemorrhage 1

Common Pitfalls to Avoid

• Do not routinely administer prophylactic antiseizure medications—this increases adverse events and worsens functional outcomes without preventing seizures 1, 5
• Do not assume a negative head CT rules out subarachnoid hemorrhage if symptoms have been present >6 hours; obtain LP or CTA for definitive diagnosis 4
• Do not delay benzodiazepine administration for an actively seizing patient—status epilepticus is defined as 5 minutes of continuous seizure activity 2, 3
• Do not continue prophylactic antiseizure medications beyond 7 days if they are used, as longer duration provides no additional benefit 5
• Do not miss non-convulsive seizures in patients with unexplained altered mental status—obtain continuous EEG 1